Dechra Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Dechra Pharmaceuticals PLC
Traded asLSEDPH
Key people
Tony Rice, (Chairman)
Ian Page, (CEO)
Revenue£407.1 million (2018)[1]
£99.2 million (2018)[1]
£36.1 million (2018)[1]

Dechra Pharmaceuticals PLC is an England-based manufacturer of veterinary products. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.


The Company was founded in 1997 by way of a management buy-out from Lloyds Chemists.[2] It was first listed on the London Stock Exchange in 2000.[2] In 2007 it bought VetXX, a Danish veterinary products business, for £62m.[3] It sold its veterinary services business to US-firm, Patterson Companies, for £87.5m in July 2013 in order to focus on its higher margin manufacturing business.[4]


The Company sells pharmaceuticals - mainly for dogs, cats, equine and food producing animals; products include Vetoryl for Cushing's disease in dogs and Felimazole for hyperthyroidism in cats. It is organised into two divisions: European Pharmaceuticals and US Pharmaceuticals.[5]

See also[edit]


  1. ^ a b c "Annual Report 2018". Dechra Pharmaceuticals. Retrieved 17 March 2019.
  2. ^ a b Montague Private Equity announces sale of VetXX
  3. ^ "Dechra Pharma to buy VetXX for 61.7 mln stg". Reuters. Retrieved 28 March 2015.
  4. ^ "Dechra sells up". Investors Chronicle. 11 July 2013. Retrieved 16 March 2014.
  5. ^ "Dechra Pharmaceuticals PLC". Retrieved 28 March 2015.